Full-Time

Database Site Reliability Engineer

SQL

Posted on 2/13/2026

Deadline 2/21/26
Lilly USA

Lilly USA

10,001+ employees

Global pharmaceutical company developing medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
DevOps & Infrastructure (1)
Requirements
  • Bachelor’s degree in Computer Science, Information Technology, Master of Computer Applications, or a related technical field
Responsibilities
  • Operational Support: Provide day-to-day administration, monitoring, and support for SQL Server all the editions (2014, 2016 and above). Manage database performance tuning, backup/recovery, patching, and upgrades. Ensure database availability, resiliency, and security compliance. Handle database incidents, requests and changes. Provide 24x7 production support with on-call rotation during weekends.
  • Database Administration: Install, configure, upgrade, and patch Microsoft SQL Server (SQL 2014 and above all editions). Monitor database performance, tuning queries, indexes, and optimizing execution plans. Troubleshoot database issues, errors, and performance bottlenecks. Work closely with application teams to support new server and database creations, maintenance job creation, CDC configuration.
  • Multi-cloud Database Modernization: Support and administer SQL Server migrations to various Cloud platforms. Ensure to support both Homogeneous and Heterogeneous Database migration. Assist with database replication, disaster recovery solutions, and cross-cloud failover planning.
  • Automation of Operational Tasks: Develop and maintain scripts, pipelines, and Infrastructure-as-Code (IaC) (Bicep, ARM, Terraform, Ansible, Shell, Python) to automate routine database tasks. Implement AIOps practices for proactive issue detection, anomaly detection, and predictive alerting.
  • Collaboration & Continuous Improvement: Work closely with operations, application, and cloud engineering teams to deliver reliable database services. Drive innovation through automation, monitoring, and AI-driven solutions to reduce manual efforts. Document best practices, runbooks, and operational procedures.
  • Capacity Planning & Scalability: Forecast database growth, manage resource utilization, and ensure scalability to handle increasing workloads while maintaining performance.
  • Database Security & Compliance: Ensure compliance with enterprise security policies (e.g., encryption, access control, auditing, vulnerability scans). Maintain adherence to Lilly security standards as required. Ensure providing less permissions to customers accounts and manage it.
  • Backup & Recovery Management: Design, automate, and test robust backup and restore processes (full, differential, transaction log backups) by storing the backup copies in PPDM (DELL Storage solution). Regularly validate recovery time objective (RTO) and recovery point objective (RPO). Ensure high availability of PPDM storages and backups.
  • Cost Optimization & Resource Efficiency: Optimize SQL resource allocation in both on-premises and cloud (Azure SQL DB, Managed Instance, IaaS VMs). Ensure cost efficiency by monitoring and right-sizing workloads.
  • SLA & SRE Principles Enforcement: Define and enforce SLIs (Service Level Indicators), SLOs (Service Level Objectives), and SLAs (Service Level Agreements) for SQL services, aligning with SRE principles.
  • Disaster Recovery (DR) Drills & Testing: Work with DR team to perform regular DR drills to validate business continuity, ensuring systems can failover and recover as expected.
  • Documentation & Knowledge Sharing: Maintain detailed documentation of database configurations, operational runbooks, and troubleshooting guides. Share knowledge across teams to reduce operational silos.
  • Soft Skills: Strong problem-solving, troubleshooting, and analytical mindset with a focus on reliability and continuous improvement; Excellent communication and collaboration abilities to work effectively with cross-functional and global teams; Adaptability to dynamic environments and ability to manage multiple priorities in fast-paced operations; Commitment to accountability, ownership, and driving results through innovation and automation; Willingness to participate in 24×7 operational support with an on-call rotation.
Desired Qualifications
  • Exposure to AI/ML-driven monitoring or AIOps tools for predictive insights and automated remediation.
  • Familiarity with multi-cloud environments (Oracle Cloud, AWS, Azure, GCP) for database deployment and operations.
  • Experience in project management methodologies (like Agile or Scrum) will be added advantage.

Lilly is a global pharmaceutical company that discovers, develops, and sells prescription medicines to improve health outcomes. It grows its portfolio through extensive research and development, then manufactures and distributes drugs worldwide to healthcare providers who prescribe them to patients. Lilly’s products span diabetes, cancer, immunology, pain management, and other serious conditions, including diabetes treatments tirzepatide and dulaglutide. The company emphasizes safety, efficacy, and ethical practices, and protects its products from counterfeiting while partnering with organizations such as Team USA. Its approach relies on rigorous R&D, strong manufacturing, and a global distribution network to bring medicines to patients. Lilly’s goal is to help people live better lives by delivering reliable medical solutions through a global, ethical, and quality-focused operation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Indianapolis, Indiana

Founded

1876

Simplify Jobs

Simplify's Take

What believers are saying

  • International Mounjaro sales jumped to $4.4 billion in Q1 from China's reimbursement list.
  • $4.5 billion Lebanon API plant opens 2027, producing tirzepatide and retatrutide at largest scale.
  • Acquires Scorpion's PI3Kα inhibitor, bolstering oncology pipeline beyond Verzenio.

What critics are saying

  • Novo Nordisk's Wegovy scaling erodes Lilly's US GLP-1 share below 25% into 2027.
  • FDA scrutiny delays Foundayo launch after May 4 hepatic failure, losing $2-3B Q4 revenue.
  • Shareholder demands force independent board chair, dropping stock 10-15% in 12 months.

What makes Lilly USA unique

  • Mounjaro generated $8.66 billion in Q1 2026 sales, surpassing Keytruda as world's best-selling drug.
  • Launched first genetic medicine facility in Lebanon on May 6, 2026, for Alzheimer's and ALS.
  • Partnered with Profluent Bio for up to $2.25 billion AI-driven DNA editing tools on May 5.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Flexible Work Hours

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-4%
The Lebanon Reporter
May 7th, 2026
Lilly invests additional $4.5B in LEAP district, opens first genetic medicine facility

Eli Lilly has announced an additional $4.5 billion investment in its Lebanon, Indiana facilities, bringing its total investment in the LEAP Innovation and Research district to $21 billion. The company opened its first Advanced Therapies site on Wednesday, marking the first operational facility in the 9,000-acre LEAP district. The new funding will support Lilly's Advanced Therapies laboratory and an active pharmaceutical ingredient facility expected to open in 2027. The Advanced Therapies site is Lilly's first dedicated genetic medicine manufacturing facility, focusing on molecular-level research for diseases including Alzheimer's, Parkinson's and ALS. Lilly is developing three facilities across 800 acres in LEAP, including a Medicine Foundry. The Advanced Therapies facility aims to accelerate delivery of breakthrough genetic medicines to patients.

AI Software Services
May 5th, 2026
Unlocking AI innovation in finance medicine and music.

Unlocking AI innovation in finance medicine and music. Published on May 05, 2026 GENETIC MEDICINE REVOLUTION: AI AND BIOTECH JOIN FORCES. In a groundbreaking partnership, Lilly and AI-driven Profluent Bio are teaming up in a deal worth up to $2.25 billion to develop advanced DNA editing tools. Their goal? To create precise treatments for genetic conditions that currently lack effective solutions, using innovative AI models to design enzymes that can target multiple mutations in the genome. This collaboration aims to unlock the "holy grail" of genetic medicine through kilobase-scale DNA editing. This matters because it could transform how AI Software Services treat genetic diseases, offering hope to millions who suffer from conditions deemed untreatable. The tools being developed are likely to be accessible, lowering barriers to entry in a field that has traditionally been expensive and exclusive. Imagine a startup that provides a platform for creators and developers to access these AI-driven genetic editing tools, enabling them to innovate and create personalized therapies. This could attract investors eager to support the next wave of medical breakthroughs!

The Economic Times
May 4th, 2026
French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly.

French fines over anti-obesity adverts for Novo Nordisk, Eli Lilly. The ANSM fined Novo Nordisk 783,838 euros regarding adverts for Wegovy and also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." * Updated On May 4, 2026 at 05:54 PM IST Paris: France's medicine safety agency ANSM said Monday it had imposed fines on pharmaceutical firms Novo Nordisk and Eli Lilly over their advertising campaigns on obesity. The agency fined on Novo Nordisk France 1.78 million euros ($2.08 million) - a million relating to adverts promoting its Saxenda drug and 783,838 euros regarding adverts for Wegovy weight management medication for treating obesity. The ANSM also fined Lilly France 108,766 euros for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as "likely to constitute indirect promotion of medicines subject to mandatory medical prescription." French laws prohibit any advertising to the general public of the treatments. The national medicines regulator said that the fines aimed to "prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves." Event. * Fri, 24 Jul 2026 * Le Meridien, Hyderabad The ANSM said the advertising campaigns were "likely to mislead the public in a context marked by extensive media coverage" as well as what it termed growing inappropriate use of medications which activate certain hormones in order notably to reduce appetite,and aid weight loss. In a statement to AFP, Novo Nordisk France said it "strongly contests" the ANSM's finding, adding it is "exploring all possible appeal avenues against this decision". Lilly France said it noted ANSM's decision, while stating it believes its awareness campaign entitled "Obesity is a sick person's problem" from a year ago was "in line with the framework applicable to communications relating to human health". According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese.

NBC News
Apr 14th, 2026
FDA requests more safety data from Lilly on weight loss pill Foundayo

The FDA is requesting additional safety data from Eli Lilly for its weight loss pill Foundayo, including information on potential heart and liver problems, according to the approval letter published Tuesday. The agency wants more data on risks including heart attacks, strokes, drug-induced liver injuries and delayed stomach emptying. Foundayo, approved this month under a fast-track pilot programme, is the second oral GLP-1 to reach market after Novo Nordisk's Wegovy pill. The FDA is also asking Lilly to collect thyroid cancer risk data for at least 15 years. The requests are considered routine for newly approved drugs, particularly for orforglipron, Foundayo's active ingredient, which has less safety data than older GLP-1s. Lilly must also establish registries tracking children with obesity and pregnancy outcomes.

PR Newswire
Apr 14th, 2026
Vasa Therapeutics partners with Lilly TuneLab to accelerate AI-driven CAMKII inhibitor development

Vasa Therapeutics, a clinical-stage biopharmaceutical company, has partnered with Eli Lilly to use Lilly TuneLab, an AI-enabled drug discovery platform that provides access to models trained on Lilly's proprietary research data. Vasa will use the platform to accelerate development of its CAMKII delta inhibitor, which is planned for Phase 1 clinical trials in 2027. The company's VS-041 is currently in a proof-of-mechanism trial for heart failure, whilst VS-214 is on track for first-in-human trials in 2026. The platform uses federated learning, allowing companies to access Lilly's AI models whilst maintaining data privacy. Vasa will contribute its own experimental datasets to support the platform's improvement. The company focuses on developing therapies for cardiovascular, neuromuscular and age-related disorders.

INACTIVE